Accordingly, our approach consisted of a detailed comparison of the kinetics, function, and phenotype of the CD8+ T cells induced by either experimental infection or immunization with recombinant adenoviral vaccine expressing the immunodominant antigen, amastigote surface protein 2, of T. cruzi (AdASP-2). The gene discussed is CD8A; the disease is infection.